← REGULATORY CHANGES
FEDERAL REGISTER · RULEJune 22, 2026IN FORCE

Medical Devices; Immunology and Microbiology Devices; Classification of the Simple In Vitro Diagnostic Device for the Detection of Secreted Proteins From Bacillus Species (spp.) in Human Clinical Samples

What this record is not

Document details are published in the U.S. Federal Register; SPEQ surfaces them for reference and is not affiliated with or endorsed by the FDA or the Office of the Federal Register. The authoritative text is on federalregister.gov.

STATUSIN FORCE
EFFECTIVEJun 22, 2026
COMMENTS CLOSE—
APPLIES TO · SPEQ TAGDevice
Document type
Rule
Agency
Health and Human Services Department
Published
June 22, 2026
Effective
June 22, 2026
Document number
2026-12443
CFR references
21 CFR 866
Docket
FDA-2026-N-6239
ABSTRACT

The Food and Drug Administration (FDA) is classifying the simple in vitro diagnostic device for the detection of secreted proteins from Bacillus species (spp.) in human clinical samples into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for classification of the simple in vitro diagnostic device for the detection of secreted proteins from Bacillus species (spp.) in human clinical samples. We are taking this action because we have determined that classifying the device into class II will provide a reasonable assurance of safety and effectiveness of the device. We believe this action will also enhance patients' access to beneficial innovative devices, in part by reducing regulatory burdens.

Abstract as published in the Federal Register.